# Nimacimab PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/nimacimab

> The next catalyst for nimacimab, sponsored by Skye Bioscience, Inc. (SKYE), is its primary completion, November 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | nimacimab |
| Codes |  |
| Sponsor | Skye Bioscience, Inc. (SKYE) https://sec-api.dev/companies/skye/catalysts |
| Indications | overweight and obesity, [Obesity](https://sec-api.dev/indications/obesity) |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### Aug 2024: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-03-20, last confirmed 2025-03-20.
- SEC Form 10-K (accession 0001516551-25-000027): "In August 2024, we initiated a 26 week Phase 2a proof-of-concept trial with a 13 week follow up, CBeyondTM for nimacimab in obesity." https://www.sec.gov/Archives/edgar/data/1516551/000151655125000027/skye-20241231.htm
- SEC Form 10-K (accession 0001516551-25-000027): "In August of 2024, we commenced our Phase 2a clinical trial, CBeyondTM, for nimacimab." https://www.sec.gov/Archives/edgar/data/1516551/000151655125000027/skye-20241231.htm

### May 8, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-05-08, last confirmed 2025-05-08.
- Press release filed with the SEC (EX-99) (accession 0001516551-25-000043): "Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity" https://www.sec.gov/Archives/edgar/data/1516551/000151655125000043/skye-20250331xearningspr.htm

### Q4 2025: topline data readout

- Status: delayed. Date confidence: quarter. Stage: 2. Indication: overweight and obesity.
- First seen 2025-03-20, last confirmed 2025-08-07.
- Press release filed with the SEC (EX-99) (accession 0001516551-25-000050): "•Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025" https://www.sec.gov/Archives/edgar/data/1516551/000151655125000050/skye-20250630xfinancialres.htm
- Press release filed with the SEC (EX-99) (accession 0001516551-25-000043): "•Top-line data readout from CBeyond™ Phase 2a study of nimacimab expected late Q3/early Q4 2025" https://www.sec.gov/Archives/edgar/data/1516551/000151655125000043/skye-20250331xearningspr.htm
- SEC Form 10-K (accession 0001516551-25-000027): "We are now conducting a Phase 2a proof-of-concept trial of nimacimab in people with overweight and obesity and expect to report a top-line readout late in the third quarter or early in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1516551/000151655125000027/skye-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001516551-25-000028): "•Faster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ahead of schedule; interim analysis removed" https://www.sec.gov/Archives/edgar/data/1516551/000151655125000028/a250320_skyexye24financial.htm
- SEC Form 10-Q (accession 0001516551-25-000042): "We anticipate providing a top-line readout from the CBeyond™ study late in the third quarter or early in the fourth quarter of 2025, enabling a comprehensive view of nimacimab's safety and efficacy profile." https://www.sec.gov/Archives/edgar/data/1516551/000151655125000042/skye-20250331.htm
- SEC Form 10-K (accession 0001516551-25-000027): "We anticipate providing a top-line readout from the CBeyond™ study late in the third quarter or early in the fourth quarter of 2025, enabling a comprehensive view of nimacimab's safety and efficacy profile." https://www.sec.gov/Archives/edgar/data/1516551/000151655125000027/skye-20241231.htm
- SEC Form 10-Q (accession 0001516551-25-000049): "We anticipate providing a top-line readout from the CBeyond study late in the third quarter or early in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1516551/000151655125000049/skye-20250630.htm
- Press release filed with the SEC (EX-99) (accession 0001516551-25-000050): ""As we eagerly await the 26-week top-line data from our CBeyondTM Phase 2a study in late Q3/early Q4 2025 (ClinicalTrials.gov: NCT06577090), we've now begun enrolling patients in the 26-week extension portion of our CBeyond Phase 2a study, which will potentially generate up to a full 52-week data set in 2026," said Punit Dhillon, President & CEO of Skye." https://www.sec.gov/Archives/edgar/data/1516551/000151655125000050/skye-20250630xfinancialres.htm

### Q4 2025: interim data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-03-20, last confirmed 2025-03-20.
- Press release filed with the SEC (EX-99) (accession 0001516551-25-000028): "•Accelerated timeline for 26-week data to late Q3/early Q4 2025: Due to faster-than-anticipated enrollment the interim analysis has been removed and top line data is expected to be reported earlier than previously reported." https://www.sec.gov/Archives/edgar/data/1516551/000151655125000028/a250320_skyexye24financial.htm

### Mar 2026: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2026-05-11, last confirmed 2026-11-13.
- SEC Form 10-Q (accession 0001628280-26-073810): "In March 2026, the Company initiated an expansion study (Part C) of the CBeyond Phase 2a trial to assess preliminary safety and pharmacokinetic (PK) profile of nimacimab administered intravenously (IV)." https://www.sec.gov/Archives/edgar/data/1516551/000162828026073810/skye-20260930.htm
- SEC Form 10-Q (accession 0001628280-26-073810): "In March 2026, we initiated an expansion study (Part C) of the CBeyond Phase 2a trial to assess preliminary safety and pharmacokinetic (PK) profile of nimacimab administered intravenously (IV)." https://www.sec.gov/Archives/edgar/data/1516551/000162828026073810/skye-20260930.htm
- SEC Form 10-Q (accession 0001628280-26-056968): "In March 2026, the Company initiated an expansion study (Part C) of the CBeyond Phase 2a trial to assess preliminary safety and pharmacokinetic (PK) profile of nimacimab administered intravenously (IV)." https://www.sec.gov/Archives/edgar/data/1516551/000162828026056968/skye-20260630.htm
- SEC Form 10-Q (accession 0001628280-26-056968): "In March 2026, we initiated an expansion study (Part C) of the CBeyond Phase 2a trial to assess preliminary safety and pharmacokinetic (PK) profile of nimacimab administered intravenously (IV)." https://www.sec.gov/Archives/edgar/data/1516551/000162828026056968/skye-20260630.htm
- SEC Form 10-Q (accession 0001628280-26-033417): "In March 2026, we initiated an expansion study (Part C) of the CBeyond Phase 2a trial to assess preliminary safety and pharmacokinetic (PK) profile of nimacimab administered intravenously (IV)." https://www.sec.gov/Archives/edgar/data/1516551/000162828026033417/skye-20260331.htm

### Q3 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-02-02, last confirmed 2026-05-11.
- SEC Form 8-K (accession 0001628280-26-004451): "Full topline reporting of the CBeyond Phase 2a extension data including nimacimab monotherapy data and 13-week off-therapy follow-up is expected to take place in Q3 2026." https://www.sec.gov/Archives/edgar/data/1516551/000162828026004451/skye-20260202.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-004451): "Full topline reporting of the CBeyond Phase 2a extension data, including nimacimab monotherapy data and 13-week off-therapy follow-up, is expected in Q3 2026." https://www.sec.gov/Archives/edgar/data/1516551/000162828026004451/a260202_skyexnrxcombinatio.htm
- SEC Form 10-Q (accession 0001628280-26-033417): "Full topline reporting of the CBeyond Phase 2a extension data including nimacimab monotherapy data and 13-week off-therapy follow-up is expected to take place in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1516551/000162828026033417/skye-20260331.htm
- SEC Form 10-K (accession 0001628280-26-016394): "Full topline reporting of the CBeyond Phase 2a extension data including nimacimab monotherapy data and 13-week off-therapy follow-up is expected to take place in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1516551/000162828026016394/skye-20251231.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Obesity.
- First seen 2026-02-02, last confirmed 2026-11-16T22:20:01.192Z.
- SEC Form 8-K (accession 0001628280-26-004451): "The Company expects its current capital to fund projected operations and key clinical milestones into the fourth quarter of 2026, including topline data from the Phase 2a extension study of nimacimab and certain manufacturing and clinical activities, initial manufacturing runs needed to enable a subsequent trial, and planning activities, but excluding the anticipated clinical cost of a proposed Phase 2b study to evaluate higher doses of nimacimab and support combination development and additional anticipated drug manufacturing costs to resupply any such Phase 2b study." https://www.sec.gov/Archives/edgar/data/1516551/000162828026004451/skye-20260202.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-016400): "•Skye expects to report topline data from the CBeyond Expansion Study in Q4 2026." https://www.sec.gov/Archives/edgar/data/1516551/000162828026016400/a260310_skyexye25financial.htm
- SEC Form 10-Q (accession 0001628280-26-033417): "We expect to report topline data from the expansion study in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1516551/000162828026033417/skye-20260331.htm
- SEC Form 10-K (accession 0001628280-26-016394): "We expect to report topline data from the expansion study in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1516551/000162828026016394/skye-20251231.htm
- ClinicalTrials.gov: "NCT06577090 (Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Skye Bioscience, Inc.." https://clinicaltrials.gov/study/NCT06577090

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06577090 (Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Skye Bioscience, Inc.." https://clinicaltrials.gov/study/NCT06577090

## Same indication

- [ABBV-295](https://sec-api.dev/pdufa/abbv-295) (ABBV)
- [AZD6234](https://sec-api.dev/pdufa/azd6234) (AZN)
- [Berobenatide](https://sec-api.dev/pdufa/berobenatide) (PFE)
- [Cagrilintide](https://sec-api.dev/pdufa/cagrilintide) (NVO)
- [Cagrisema (cagrilintide b and semaglutide i)](https://sec-api.dev/pdufa/cagrisema-cagrilintide-b-and-semaglutide-i) (NVO)
- [Elecoglipron](https://sec-api.dev/pdufa/elecoglipron) (AZN)
- [Eloralintide](https://sec-api.dev/pdufa/eloralintide) (LLY)
- [KAI-7535](https://sec-api.dev/pdufa/kai-7535) (KLRA)
- [LY3549492](https://sec-api.dev/pdufa/ly3549492) (LLY)
- [LY4086940](https://sec-api.dev/pdufa/ly4086940) (LLY)
- [Macupatide](https://sec-api.dev/pdufa/macupatide) (LLY)
- [Maridebart cafraglutide](https://sec-api.dev/pdufa/maridebart-cafraglutide) (AMGN)
- [Met097 injection](https://sec-api.dev/pdufa/met097) (PFE)
- [NNC0487-0111](https://sec-api.dev/pdufa/nnc0487-0111) (NVO)
- [Foundayo (orforglipron calcium)](https://sec-api.dev/pdufa/orforglipron) (LLY)
- [PF-07976016](https://sec-api.dev/pdufa/pf-07976016) (PFE)
- [PF-08653944](https://sec-api.dev/pdufa/pf-08653944) (PFE)
- [Retatrutide](https://sec-api.dev/pdufa/retatrutide) (LLY)
- [Ribupatide](https://sec-api.dev/pdufa/ribupatide) (KLRA)
- [IMCIVREE® (setmelanotide)](https://sec-api.dev/pdufa/setmelanotide) (RYTM)
- [Taldefgrobep alfa](https://sec-api.dev/pdufa/taldefgrobep-alfa) (BHVN)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)
- [NEREUSTM (tradipitant)](https://sec-api.dev/pdufa/tradipitant) (VNDA)
- [Trevogrumab-part a](https://sec-api.dev/pdufa/trevogrumab-part-a) (REGN)
- [Zenagamtide](https://sec-api.dev/pdufa/zenagamtide) (NVO)

Calendar months: [November 2026](https://sec-api.dev/fda-calendar/2026-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/nimacimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Nimacimab PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/nimacimab

```bibtex
@misc{secapidev_pdufa_nimacimab_20261116,
  title        = {Nimacimab PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/nimacimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_nimacimab_20261116","title":"Nimacimab PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/nimacimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
